Therapeutic Application of Alpha-1 Antitrypsin in COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.04.02.21252580: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This approach was reported to the ethics committee of the Ärztekammer des Saarlandes. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources For SARS-2-S expressing cells as well as cells expressing no viral glycoprotein, anti-VSV-G antibody (culture supernatant from I1-hybridoma cells; ATCC no. CRL-2700) was added to the culture medium. anti-VSV-Gsuggested: NoneExperimental Models: Cell Lines Sentences Resources VSV pseudotype particles bearing SARS-2-S, VSV-G or no viral protein (negative control) were produced using … SciScore for 10.1101/2021.04.02.21252580: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This approach was reported to the ethics committee of the Ärztekammer des Saarlandes. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources For SARS-2-S expressing cells as well as cells expressing no viral glycoprotein, anti-VSV-G antibody (culture supernatant from I1-hybridoma cells; ATCC no. CRL-2700) was added to the culture medium. anti-VSV-Gsuggested: NoneExperimental Models: Cell Lines Sentences Resources VSV pseudotype particles bearing SARS-2-S, VSV-G or no viral protein (negative control) were produced using an established protocol (18): First, HEK-293T cells were transfected to express the respective viral protein or no viral protein. HEK-293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)For transduction experiments, Calu-3 cells (grown in 96-well plates) were preincubated with different concentrations of AAT (Kamada, diluted in culture medium) or culture medium alone. Calu-3suggested: NoneFor virus titration, Vero E6 cells were grown in 12-well plates until reaching confluency. Vero E6suggested: NoneSoftware and Algorithms Sentences Resources Data were analyzed with Microsoft Excel (Microsoft, Redmond, USA) Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)), SPSS 28 (IBM, Ehningen, Germany) and graphed using GraphPad Prism 8 Software (San Diego, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has limitations that need to be addressed, first of all the lack of data from a controlled trial and the missing deep mechanistic characterization of the mode of action of AAT. These items are beyond this report, which shows that AAT has anti-SARS-CoV-2 activity, is well tolerated in patients with COVID-19 and together with its anti-inflammatory properties can be considered a promising candidate for treatment of COVID-19 that should be further evaluated in a randomized controlled trial for inhaled and / or intravenous treatment.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04799873 Completed Alpha-1-Antitrypsin-Deficiency in COVID-19 Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
